Use of the QuantiFERON-TB Gold In-Tube Test in the Diagnosis and Monitoring of Treatment Efficacy in Active Pulmonary Tuberculosis
Autor: | Ping-Chin Chang, Pin-Hui Wang, Kow-Tong Chen |
---|---|
Rok vydání: | 2017 |
Předmět: |
Male
0301 basic medicine medicine.medical_specialty Tuberculosis QUANTIFERON-TB GOLD Health Toxicology and Mutagenesis 030106 microbiology Antitubercular Agents specificity lcsh:Medicine QuantiFERON-TB Gold In-Tube test pulmonary tuberculosis sensitivity biology_other Sensitivity and Specificity Article QuantiFERON Sputum culture Interferon-gamma 03 medical and health sciences 0302 clinical medicine Pulmonary tuberculosis Internal medicine medicine Humans In patient 030212 general & internal medicine Tuberculosis Disease Tuberculosis Pulmonary Aged medicine.diagnostic_test business.industry lcsh:R Sputum Public Health Environmental and Occupational Health Middle Aged medicine.disease Treatment efficacy Surgery Treatment Outcome Biological Assay Female Gold Reagent Kits Diagnostic medicine.symptom business |
Zdroj: | International Journal of Environmental Research and Public Health, Vol 14, Iss 3, p 236 (2017) International Journal of Environmental Research and Public Health International Journal of Environmental Research and Public Health; Volume 14; Issue 3; Pages: 236 |
ISSN: | 1660-4601 |
Popis: | The value of QuantiFERON in the diagnosis of tuberculosis and in the monitoring of the response to anti-tuberculosis treatment is unclear. The aims of this study were to evaluate the accuracy of the QuantiFERON-TB Gold In-Tube (QFT-GIT) test in the diagnosis of tuberculosis and in the monitoring of the response to anti-tuberculosis treatment in patients with active pulmonary tuberculosis (PTB). Between January 2013 and December 2015, 128 cases with active PTB and 128 controls with no mycobacterial infection, matched by age (within 3 years) and by the week that they visited Tainan Chest Hospital, were enrolled in the study. Serial testing by QFT-GIT at baseline and after 2 and 6 months of treatment was performed. At these time points, a comparison of the performance of QFT-GIT with that of sputum culture status among study subjects was conducted. Compared to baseline, 116 (87.2%) cases showed a decreased response, whereas 17 (12.8%) showed persistent or stronger interferon-gamma (IFN-γ) responses at 2 months. Their IFN-γ responses declined significantly from baseline to 2 months (median, 6.32 vs. 4.12; P < 0.005). The sensitivity values of the QFT-GIT test for the detection of pulmonary tuberculosis at cut-off points of 0.35 IU/ml, 0.20 IU/ml, and 0.10 IU/ml were 74.4%, 78.2%, and 80.5%, respectively. The specificity values at cut-off points of 0.35 IU/ml, 0.20 IU/ml, and 0.10 IU/ml were 66.2%, 63.9%, and 57.1%, respectively. Our results support the QFT-GIT assay as a potential tool for diagnosing tuberculosis and for monitoring the efficacy of anti-tuberculosis treatment. |
Databáze: | OpenAIRE |
Externí odkaz: |